H
Heparegenix
Biotech & Life Sciences · Tübingen, Germany · Founded 2015
Preclinical stage company developing novel therapies for the treatment of acute and chronic liver diseases MoreLess
HepaRegeniX is a biotechnology company focused on discovering and developing innovative drug candidates to treat multiple liver diseases. The company's primary market includes healthcare providers, pharmaceutical companies, and research institutions. HepaRegeniX operates in the biotechnology and pharmaceutical sectors, targeting unmet medical needs in liver disease treatment. The business model revolves around the research and development of proprietary drug candidates, which are then advanced through clinical trials. Revenue is generated through funding rounds, partnerships, and potential future licensing deals or sales of developed drugs. Recently, HepaRegeniX raised a Series C funding round to further the clinical development of its lead candidate, HRX 215, aimed at liver regeneration. Keywords: biotechnology, liver disease, drug development, clinical trials, healthcare, pharmaceutical, liver regeneration, HRX 215, Series C funding, innovation.
Company overview
Heparegenix company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2015
- Headquarters
- Tübingen, Germany
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 58.9
Valuation & funding
Heparegenix funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jun 2025 | $0 | — | Wellington Partners · Novo Holdings · Vesalius Biocapital Partners | — |
| LATE VCOther financing | Apr 2025 | $24M | $95M | Wellington Partners | ↗ |
| SERIES COther financing | Jul 2024 | $17M | $66M | HTGF · Boehringer Ingelheim Venture Fund · Novo Holdings · Vesalius Biocapital Partners | ↗ |
| SERIES BOther financing | Jan 2020 | $12M | $49M | Boehringer Ingelheim Venture Fund · HTGF · Ascenion GmbH · Novo Holdings | — |
| SERIES AOther financing | Dec 2016 | $9.9M | $40M | Boehringer Ingelheim Venture Fund · Novo Seeds | — |
| SPINOUTOther financing | Jan 2015 | Helmholtz Association - Helmholtz Gemeinschaft | — |
Growth signals
Heparegenix website traffic
Latest recorded traffic for Heparegenix is 400 monthly website visits, up 400% over the last three months. Heparegenix's team grew 0% over the past year.
Comparisons
Heparegenix compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Heparegenix's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Heparegenix has talent and traffic
team presence
In the news
Latest news about Heparegenix
Recent press, funding announcements, and product moves mentioning Heparegenix — open to read from the original sources.
Market sentiment
What the market is saying about Heparegenix
An AI-synthesized read of the highest-engagement posts about Heparegenix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Heparegenix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.